Medical/Pharmaceuticals
HKEY-AI4AI-Atlas™ 1.0: HKeyBio Uses AI to Curate Autoimmune Model Datasets
HKEY-AI4AI-Atlas™ 1.0 uses AI-assisted dataset curation to support model selection, endpoint design and cross-species interpretation BOSTON and SUZHOU, China, July 22, 2026 /PRNewswire/ -- HKeyBio is building HKEY-AI4AI-Atlas™ 1.0, its AI-Assisted Autoimmune Model Data Atlas. The internal capabi...
2026-07-22 21:16
887
Targeting the $100 Billion Market: Insilico Medicine Nominates AI-driven Novel PCC ISM9528 for Pain Management
* AI-Driven New Mechanism Discovery: Targeting an undisclosed novel mechanism empowered by PandaOmics, the PCC ISM9528 offers a potential first-in-class,brain -penetrant, non-opioid solution for pain management. * Superior Therapeutic Profile: In preclinical studies, ISM9528 demonstrated super...
2026-07-22 21:00
1426
China Pharma Holdings, Inc. Comments on Unusual Market Activity
HAIKOU, China, July 21, 2026 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma" or the "Company"), a fully-integrated specialty pharmaceuticals company in China, today announced that, in view of the unusual market activity in the common stock of China Pharma on July...
2026-07-22 04:00
1568
The Second Battlefield for Solid Tumor CAR-T: A Global Race in the Intracranial Arena -- Who Is Leading?
T-MAXIMUM PHARMACEUTICAL Inc's Universal CAR-T First-in-Human Data to Debut at the World Conference on Lung Cancer BEIJING, July 21, 2026 /PRNewswire/ -- Recently, the 2026 World Conference on Lung Cancer (WCLC) released a set of abstracts that drew notable industry attention: preliminary first-...
2026-07-21 20:30
2268
Alebund Pharmaceuticals Announces First Participant Randomized and Dosed in Global Phase IIb Multi-Regional Clinical Trial of AP306 for Hyperphosphatemia
SHANGHAI, July 21, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; HKEX: 09637), a renal-focused biopharmaceutical company, today announced that the first participant has been randomized and dosed in the global Phase IIb multi-regional clinical trial of...
2026-07-21 19:00
1731
Rege Nephro Secures approximately US$10.6 Million to Advance RN-014 Toward Commercialization
Financing will support development of RN-014 and RN-032 and continued expansion of the company's kidney disease pipeline KYOTO, Japan, July 21, 2026 /PRNewswire/ -- Rege Nephro Co., Ltd. ("Rege Nephro"), a clinical-stage biotechnology company focused on iPS cell-based kidney regenerative medicin...
2026-07-21 12:00
1266
ESMO 2026 | Mabwell to Present Latest Clinical Data on Nectin-4-targeting ADC 9MW2821 for Triple Negative Breast Cancer in Oral Presentation
SHANGHAI, July 20, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, will present the latest clinical study results of its novel Nectin‑4‑targeting ADC, 9MW2821, for triple‑negative breast cancer in an oral ...
2026-07-21 11:50
1718
SuanNutra, Parent Company of Monteloeder and a Carbyne Equity Partners Portfolio Company, Expands Product Portfolio with Specialty Natural Ingredients Businesses from IFF
MADRID, July 20, 2026 /PRNewswire/ -- SuanNutra, the global science-backed ingredients group, today announced it has signed an agreement to acquire a portfolio of specialty natural ingredients businesses from IFF (NYSE: IFF). The transaction, backed by SuanNutra's majority shareholder Carbyne Equ...
2026-07-21 07:30
4016
PharmaBlock Convenes Global Industry Leaders in Zurich to Advance Green Chemistry for Sustainable Pharmaceutical Manufacturing
ZURICH, July 20, 2026 /PRNewswire/ -- As Europe experienced one of its hottest Junes on record, with prolonged heatwaves reinforcing the urgency of climate action, leaders from the pharmaceutical industry and academia gathered in Zurich for thePharmaBlock's 3rd Green Chemistry Symposium (GCS) to ...
2026-07-20 20:00
3328
Fostering new opportunities in the Greater Bay Area and Asia's Pharmaceutical Industry
SHANGHAI, July 20, 2026 /PRNewswire/ -- Following the landmark success of CPHI & PMEC China in June 2026, which welcomed an unprecedented gathering of industry professionals and fostered pivotal connections across the pharmaceutical supply chain, attention now shifts to South China. Building on ...
2026-07-20 13:47
1292
Akeso Doses First Patient in Phase II Study of Novel TROP2/Nectin-4 Bispecific ADC (AK146D1) in Combination with Ivonescimab for Advanced NSCLC
HONG KONG, July 20, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that the first patient has been dosed in a Phase II clinical study (AK146D1-201) evaluating its internally developed TROP2/Nectin-4 bispecific antibody-drug conjugate (ADC), AK146D1, in combi...
2026-07-20 13:32
2102
Neuronata-R retains conditional approval in South Korea
South Korea's Ministry of Food and Drug Safety (MFDS) updates the stem cell therapy's approval in May 2026 — as the developer works to resume supply and build a U.S. research base SEOUL, South Korea, July 19, 2026 /PRNewswire/ -- Patients with amyotrophic lateral sclerosis (ALS) in South Korea w...
2026-07-20 07:00
1598
Samsung Biologics announces all-cash offer to acquire PolyPeptide, accelerating multi-modality strategy and expanding global network across U.S., Europe, and India
* Samsung Biologics to launch an all-cash public tender offer for 100% of PolyPeptide's fully diluted share capital (excluding therefrom any treasury shares) at CHF 44.31 per share, representing an equity value of approximately CHF 1.46 billion. * Strong transaction support, with a unanimous ...
2026-07-20 06:43
3437
HEALEY ALS Platform Trial Regimen I enrolment completed - Topline results for NUZ-001 accelerated to Q2 CY2027
* 250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY ALS Platform Trial so far * Anticipated topline efficacy and safety results for NUZ-001 now expected in late Q2 CY2027 * Completion of rec...
2026-07-17 11:48
5375
HoneyNaps Receives U.S. FDA 510(k) Clearance for SOMNUM V3.0 for AI-Based Sleep-Disordered Breathing Analysis
- FDA 510(k) Clearance (K253390) Validates AI-Based Classification of OSA, CSA, and MSA - Subtype-Specific Respiratory Event Analysis Improves Diagnostic Precision and Supports Next-Generation Digital Biomarker Development - Advanced AI Analysis Using Multi-Channel Physiological Signals, with Add...
2026-07-16 18:00
2635
China Pharma Holdings, Inc. States It Knows of No Events That Could Have Caused Unusual Market Activity
HAIKOU, China, July 15, 2026 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma" or the "Company"), a fully-integrated specialty pharmaceuticals company in China, today announced that, in view of the unusual market activity in the common stock of China Pharma on July...
2026-07-16 00:12
6389
Seegene: "Virus-Only Testing May Miss Pneumonia-associated Bacterial Respiratory Pathogens" Calls for a Shift to Comprehensive Syndromic PCR Testing
* Virus-only testing may miss pneumonia-associated bacterial co-detections in 78% of virus-positive cases, while bacteria-only testing may miss viral co-detections in 88% of cases positive for pneumonia-associated bacterial pathogens * Global Million Clinical Study (GMCS) to build clinical ev...
2026-07-15 21:00
5586
Bambusa Therapeutics Appoints Howard Liang, Ph.D. to its Board of Directors and Establishes Scientific Advisory Board
Dr. Liang brings deep biopharma finance, strategy, and capital markets expertise to support the company's next phase of growth Bambusa also forms a Scientific Advisory Board of globally recognized leaders in biopharma, dermatology, and respiratory medicine to guide its immunology and inflammatio...
2026-07-15 21:00
5125
Ractigen Therapeutics Announces Landmark Publication in Nature Medicine Highlighting Unprecedented Preclinical Efficacy and Positive First-in-Human Clinical Data for RAG-17 in SOD1-ALS
— Peer-reviewed publication details RAG-17's robust translation from "bench to bedside," validating the proprietary SCAD™ delivery platform for CNS-targeted RNAi therapies — — First-in-Human trial met primary safety endpoints with no Serious Adverse Events (SAEs); demonstrated mean reductions of...
2026-07-15 20:47
3709
POMDOCTOR LIMITED Advances Healthcare Data Asset Strategy to Strengthen AI-Powered Chronic Disease Management Capabilities
GUANGZHOU, China, July 15, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and predictive healthcare capabilities, today highlighted its ongoing efforts to strengthen its health...
2026-07-15 20:00
3258
Week's Top Stories
Most Reposted
Visa Reimagines Visa Infinite for Asia Pacific's Modern Affluent
[Picked up by 305 media titles]
2026-07-16 10:00
Ascentium Welcomes MGI Dobbyn Carafa, Strengthening Advisory Capability in Australia
[Picked up by 295 media titles]
2026-07-20 15:00
Singapore Tourism Board and Traveloka Renew Partnership to Welcome More Southeast Asian and Australian Travellers to Singapore
[Picked up by 291 media titles]
2026-07-17 18:18
Klook signs an expanded two-year partnership with Korea Tourism Organization
[Picked up by 288 media titles]
2026-07-16 17:49
Omni HR Launches Native MCP Integration, Connecting AI Assistants to Live HR Data
[Picked up by 286 media titles]
2026-07-20 11:00
Most Read
Visa Reimagines Visa Infinite for Asia Pacific's Modern Affluent
2026-07-16 10:00
15461
Klook signs an expanded two-year partnership with Korea Tourism Organization
2026-07-16 17:49
10953